Viscoelastic tests in liver disease: where do we stand now? - PubMed (original) (raw)
Review
Viscoelastic tests in liver disease: where do we stand now?
Alina Buliarca et al. World J Gastroenterol. 2021.
Abstract
Hemostasis is a complex physiological process based on the balance between pro-coagulant and anticoagulant systems to avoid pathological bleeding or thrombosis. The changes in standard coagulation tests in liver disease were assumed to reflect an acquired bleeding disorder, and cirrhotic patients were considered naturally anticoagulated. In the light of the new evidence, the theory of rebalanced hemostasis replaced the old concept. According to this model, the hemostatic alteration leads to a unique balance between pro-coagulant, anticoagulant, and fibrinolytic systems. But the balance is fragile and may prone to bleeding or thrombosis depending on various risk factors. The standard coagulation tests [INR (international normalized ratio), platelet count and fibrinogen] only explore parts of the hemostasis, not offering an entire image of the process. Rotational thromboelastometry (ROTEM) and thromboelastography (TEG) are both point of care viscoelastic tests (VET) that provide real-time and dynamic information about the entire hemostasis process, including clot initiation (thrombin generation), clot kinetics, clot strength, and clot stability (lysis). Despite prolonged PT/INR (international normalized ratio of prothrombin time) and low platelet counts, VET is within the normal range in many patients with both acute and chronic liver disease. However, bleeding remains the dominant clinical issue in patients with liver diseases, especially when invasive interventions are required. VET has been shown to asses more appropriately the risk of bleeding than conventional laboratory tests, leading to decrial use of blood products transfusion. Inappropriate clotting is common but often subtle and may be challenging to predict even with the help of VET. Although VET has shown its benefit, more studies are needed to establish cut-off values for TEG and ROTEM in these populations and standardization of transfusion guidelines before invasive interventions in cirrhotic patients/orthotopic liver transplantation.
Keywords: Acute-on-chronic liver failure; Bleeding risk; Invasive procedures; Liver diseases; Portal vein thrombosis; Viscoelastic tests.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors have no other disclosures.
Figures
Figure 1
Rebalanced hemostasis in liver cirrhosis. In primary hemostasis, high levels of von Willebrand factor and low levels of disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 counteract numerical or functional abnormalities of platelets. In the coagulation phase, low levels of procoagulant proteins are balanced by reduced synthesis of anticoagulant factors. In fibrinolysis, parallel changes are seen in profibrinolytic and antifibrinolytic proteins. The balance is though fragile, and various factors, as inflammation, infection, uremia may unstable it, leading to bleeding or thrombosis. tPA: Tissue plasminogen activator; TAFI: Thrombin-activatable fibrinolysis inhibitor; vWF: von Willebrand factor; ADAMTS13: Disintegrin and metalloproteinase with a thrombospondin type 1 motif 13; PAI-1: Plasminogen activator inhibitor-1.
Figure 2
Parameters of viscoelastic tests graphical. TEG: Thromboelastography; ROTEM: Rotational thromboelastometry; CFT: Clot formation time; CT: Clotting time; R: Reaction time; K: K time; MA: Maximum amplitude; MCF: Maxmum clot firmness; CLI30: Clot lysis index at 30 min after maximum clot firmness; Ly30: Clot lysis at 30 min after maximum amplitude; CLI60: Clot lysis index at 60 min after maximum clot firmness; Ly60: Clot lysis at 60 min after maximum amplitude.
Similar articles
- Clinical Utility of Viscoelastic Tests of Coagulation (TEG/ROTEM) in Patients with Liver Disease and during Liver Transplantation.
Mallett SV. Mallett SV. Semin Thromb Hemost. 2015 Jul;41(5):527-37. doi: 10.1055/s-0035-1550434. Epub 2015 Jun 6. Semin Thromb Hemost. 2015. PMID: 26049072 Review. - Hemostasis testing in patients with liver dysfunction: Advantages and caveats.
Nguyen G, Lejeune M, Crichi B, Frere C. Nguyen G, et al. World J Gastroenterol. 2021 Nov 14;27(42):7285-7298. doi: 10.3748/wjg.v27.i42.7285. World J Gastroenterol. 2021. PMID: 34876789 Free PMC article. Review. - Viscoelastic Tests as Point-of-Care Tests in the Assessment and Management of Bleeding and Thrombosis in Liver Disease.
Janko N, Majeed A, Kemp W, Roberts SK. Janko N, et al. Semin Thromb Hemost. 2020 Sep;46(6):704-715. doi: 10.1055/s-0040-1715475. Epub 2020 Sep 15. Semin Thromb Hemost. 2020. PMID: 32932542 Review. - AGA Clinical Practice Update: Coagulation in Cirrhosis.
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. O'Leary JG, et al. Gastroenterology. 2019 Jul;157(1):34-43.e1. doi: 10.1053/j.gastro.2019.03.070. Epub 2019 Apr 12. Gastroenterology. 2019. PMID: 30986390 Review. - Coagulation, hemostasis, and transfusion during liver transplantation.
Thai C, Oben C, Wagener G. Thai C, et al. Best Pract Res Clin Anaesthesiol. 2020 Mar;34(1):79-87. doi: 10.1016/j.bpa.2020.03.002. Epub 2020 Mar 16. Best Pract Res Clin Anaesthesiol. 2020. PMID: 32334789 Review.
Cited by
- Stroke, Thrombosis, Bleeding and Addiction to Anticoagulants in the Context of Course Therapy: A Pharmacologic Perspective.
Urakov A, Stolyarenko A, Yagudin I, Mukhutdinov N, Bashirov I. Urakov A, et al. Rev Cardiovasc Med. 2022 Jun 24;23(7):236. doi: 10.31083/j.rcm2307236. eCollection 2022 Jul. Rev Cardiovasc Med. 2022. PMID: 39076898 Free PMC article. - Surgical risk stratification in patients with cirrhosis.
Ostojic A, Mahmud N, Reddy KR. Ostojic A, et al. Hepatol Int. 2024 Jun;18(3):876-891. doi: 10.1007/s12072-024-10644-y. Epub 2024 Mar 12. Hepatol Int. 2024. PMID: 38472607 Review. - Clinical Characteristics and Survival of Hepatocellular Carcinoma: Insights from Single-Centre Experience in Saudi Arabia.
Badheeb AM, Al Sedran MK, Ahmed F, Al Sidran IK, Al Qurayshah MH, Abu Bakar A, Obied HY, Seada IA, Aman A, Badheeb M. Badheeb AM, et al. Cureus. 2024 Jan 20;16(1):e52608. doi: 10.7759/cureus.52608. eCollection 2024 Jan. Cureus. 2024. PMID: 38374854 Free PMC article. - Autoimmune Hepatitis Complicated by Undiagnosed Factor VII Deficiency: A Pitfall of Coagulopathy.
Kishimoto K, Kakisaka K, Abe T, Ito A, Yusa K, Suzuki A, Endo K, Yoshida Y, Oikawa T, Miyasaka A, Sato A, Nishiya M, Yanagawa N, Kuroda H, Matsumoto T. Kishimoto K, et al. Intern Med. 2024 Jul 15;63(14):2011-2014. doi: 10.2169/internalmedicine.2854-23. Epub 2023 Nov 20. Intern Med. 2024. PMID: 37981301 Free PMC article. - Approach to thromboelastography-based transfusion in cirrhosis: An alternative perspective on coagulation disorders.
Kataria S, Juneja D, Singh O. Kataria S, et al. World J Gastroenterol. 2023 Mar 7;29(9):1460-1474. doi: 10.3748/wjg.v29.i9.1460. World J Gastroenterol. 2023. PMID: 36998429 Free PMC article. Review.
References
- Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001;85:958–965. - PubMed
- Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol. 2013;11:1064–1074. - PubMed
- Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing Concepts of Cirrhotic Coagulopathy. Am J Gastroenterol. 2017;112:274–281. - PubMed
- Kujovich JL. Coagulopathy in liver disease: a balancing act. Hematology Am Soc Hematol Educ Program. 2015;2015:243–249. - PubMed
- Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53–61. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical